Updated 2026 guidelines from major medical organizations now make more than half of U.S. adults eligible for statin therapy to manage cholesterol and heart disease risk.
Key facts
- •Approximately 87.5 million U.S. adults are now eligible for statin therapy under the 2026 guidelines.
- •Nearly 80% of adults with established heart disease have LDL cholesterol levels above the new, stricter targets.
- •The PREVENT-ASCVD tool reclassified 21.5% of adults into different cardiovascular risk categories compared to previous methods.
- •Over three-quarters of high-risk individuals in primary prevention were found to be untreated for high cholesterol.
- •The new guidelines recommend measuring lipoprotein(a) at least once to screen for inherited heart disease risk.
The American Heart Association, American College of Cardiology, and other medical groups released new cholesterol guidelines in 2026. These updates, which include lower LDL targets and a new risk assessment tool, have expanded statin eligibility to over half of U.S. adults. Three recent studies published in JAMA evaluated the impact of these changes, finding that they could improve cholesterol control and personalize cardiovascular risk management.
By the numbers
Expanded Statin Eligibility
Analysis of data from the National Health and Nutrition Examination Survey (NHANES) indicates that approximately 56.6% of U.S. adults aged 30 to 79 are now eligible for statin therapy. This includes 21.5 million people who were not recommended for such treatment under the previous 2018 guidelines. The newly eligible population is generally younger and at a lower short-term risk, with an average 10-year heart disease risk of 3.1%.
New Risk Assessment and Treatment Gaps
The 2026 guidelines introduce the PREVENT-ASCVD risk tool to replace older equations. Research shows that about 21.5% of adults were reclassified into different risk categories using this new tool, with two-thirds moving to a lower-risk category and one-third to a higher-risk category. Despite these updates, studies identified significant treatment gaps, noting that a large majority of individuals with LDL levels above recommended goals are not currently receiving cholesterol-lowering medications.
Expert Perspectives on Management
Medical experts emphasize that cholesterol management requires a comprehensive approach beyond single lab values. The guidelines now recommend universal screening for lipoprotein(a) to identify inherited risks and encourage personalized treatment plans that incorporate lifestyle changes, imaging, and medication. Clinicians note that early intervention is critical, as many patients remain unaware of their elevated cholesterol levels until cardiovascular damage has already occurred.
Timeline
- 1999-2020Data period used to evaluate the PREVENT-ASCVD risk assessment tool.
- 2017-2023Data period used to estimate the impact of guideline changes on statin eligibility.
- 2021-2023Data period used to examine cholesterol levels and treatment gaps.
- 2026The AHA, ACC, and other organizations released the new dyslipidemia guidelines.
- July 20Three studies evaluating the new guidelines were published in JAMA.
Advertisement
This article was independently rewritten by ManyPress editorial AI from reporting originally published by Healthline.
